16-18,20 Of the prescription agents listed, glucagon-like peptide-1 (GLP-1)based therapies are considered to be first-line
Clinical trials show gastrointestinal side effects (nausea, vomiting, constipation) affect 20-40% of users across semaglutide, tirzepatide, and retatrutide, but severity and persistence vary widely
Mesenchymal stem/stromal cells (MSCs) are multipotent stem cells present in virtually all adult tissues (Dominici et al., 2006
Clinical trials have demonstrated a reduced risk of major adverse cardiovascular events, such as heart attack and stroke, in individuals treated with semaglutide
Clinical observations suggest this combination accelerates results by 30-50% compared to either therapy alone